Cargando…

Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients

BACKGROUND: Diabetes mellitus is a heterogeneous group of disorders characterized by abnormalities of carbohydrate, protein and lipid metabolism. Type 1 diabetes mellitus is an autoimmune disease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Taj Eldin, Imad M., Ahmed, Elhadi M., Elwahab H.M, Abd
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978938/
https://www.ncbi.nlm.nih.gov/pubmed/21079693
http://dx.doi.org/10.4137/EHI.S5540
_version_ 1782191320625840128
author Taj Eldin, Imad M.
Ahmed, Elhadi M.
Elwahab H.M, Abd
author_facet Taj Eldin, Imad M.
Ahmed, Elhadi M.
Elwahab H.M, Abd
author_sort Taj Eldin, Imad M.
collection PubMed
description BACKGROUND: Diabetes mellitus is a heterogeneous group of disorders characterized by abnormalities of carbohydrate, protein and lipid metabolism. Type 1 diabetes mellitus is an autoimmune disease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type 2 diabetes mellitus results from abnormalities in insulin secretion and/or insulin action or both. OBJECTIVES: The present study was conducted to investigate the clinical hypoglycemic effects of Allium cepa in type 1 and type 2 diabetic patients. RESULTS: In assessment of hypoglycaemic activity of Allium cepa in type 1 and type 2 diabetic patients, ingestion of crude Allium cepa (100 g) caused a considerable reduction in fasting blood glucose levels by about 89 mg/dl in relation to insulin (145 mg/dl) in type 1 diabetic patients and it reduced fasting blood glucose levels by 40 mg/dl, compared to glibenclamide (81 mg/dl) in type 2 diabetic patients, 4 hours later. The same dose of crude Allium cepa produced a significant reduction in the induced hyperglycemia (GTT) by about 120 mg/dl compared to water (77 mg/dl) and insulin (153 mg/dl) in type 1 diabetic patients and considerably reduced GTT by 159 mg/dl in relation to water (55 mg/dl) and glibenclamide (114 mg/dl) in type 2 diabetic patients, after 4 hours. CONCLUSION: It was evident that, crude Allium cepa produced hypoglycemic effects, thus it could be used as a dietary supplement in management of type 1 and/or type 2 diabetes mellitus.
format Text
id pubmed-2978938
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-29789382010-11-15 Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients Taj Eldin, Imad M. Ahmed, Elhadi M. Elwahab H.M, Abd Environ Health Insights Original Research BACKGROUND: Diabetes mellitus is a heterogeneous group of disorders characterized by abnormalities of carbohydrate, protein and lipid metabolism. Type 1 diabetes mellitus is an autoimmune disease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type 2 diabetes mellitus results from abnormalities in insulin secretion and/or insulin action or both. OBJECTIVES: The present study was conducted to investigate the clinical hypoglycemic effects of Allium cepa in type 1 and type 2 diabetic patients. RESULTS: In assessment of hypoglycaemic activity of Allium cepa in type 1 and type 2 diabetic patients, ingestion of crude Allium cepa (100 g) caused a considerable reduction in fasting blood glucose levels by about 89 mg/dl in relation to insulin (145 mg/dl) in type 1 diabetic patients and it reduced fasting blood glucose levels by 40 mg/dl, compared to glibenclamide (81 mg/dl) in type 2 diabetic patients, 4 hours later. The same dose of crude Allium cepa produced a significant reduction in the induced hyperglycemia (GTT) by about 120 mg/dl compared to water (77 mg/dl) and insulin (153 mg/dl) in type 1 diabetic patients and considerably reduced GTT by 159 mg/dl in relation to water (55 mg/dl) and glibenclamide (114 mg/dl) in type 2 diabetic patients, after 4 hours. CONCLUSION: It was evident that, crude Allium cepa produced hypoglycemic effects, thus it could be used as a dietary supplement in management of type 1 and/or type 2 diabetes mellitus. Libertas Academica 2010-10-14 /pmc/articles/PMC2978938/ /pubmed/21079693 http://dx.doi.org/10.4137/EHI.S5540 Text en © 2010 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Original Research
Taj Eldin, Imad M.
Ahmed, Elhadi M.
Elwahab H.M, Abd
Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title_full Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title_fullStr Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title_full_unstemmed Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title_short Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients
title_sort preliminary study of the clinical hypoglycemic effects of allium cepa (red onion) in type 1 and type 2 diabetic patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978938/
https://www.ncbi.nlm.nih.gov/pubmed/21079693
http://dx.doi.org/10.4137/EHI.S5540
work_keys_str_mv AT tajeldinimadm preliminarystudyoftheclinicalhypoglycemiceffectsofalliumceparedonionintype1andtype2diabeticpatients
AT ahmedelhadim preliminarystudyoftheclinicalhypoglycemiceffectsofalliumceparedonionintype1andtype2diabeticpatients
AT elwahabhmabd preliminarystudyoftheclinicalhypoglycemiceffectsofalliumceparedonionintype1andtype2diabeticpatients